Current Report Filing (8-k)
February 17 2017 - 05:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
February 16, 2017
ABEONA THERAPEUTICS INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-15771
|
83-0221517
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
3333 Lee Parkway, Suite 600
Dallas, TX 75219
(Address of principal executive offices)
(Zip Code)
(214)-665-9495
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General
Instruction A.2. below):
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 7.01.
|
Regulation FD Disclosure
|
Presentation relating to Abeona Therapeutics
Inc. The presentation is attached as Exhibit 99.1 and is incorporated herein.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
|
99.1
|
Presentation entitled “Abeona Therapeutics”
|
|
99.2
|
Press release dated February
17, 2017, entitled “Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13
th
Annual WORLDSymposium™ 2017”
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Abeona Therapeutics Inc.
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
By:
|
/s/ Stephen B. Thompson
|
|
|
|
Stephen B. Thompson
Vice President Finance
Chief Accounting Officer
|
|
Dated: February 17, 2017
EXHIBIT INDEX
Exhibit Number
|
99.1
|
Presentation entitled “Abeona Therapeutics”
|
|
99.2
|
Press release dated February 17, 2017 entitled “Abeona
Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017”
|
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Mar 2023 to Mar 2024